Orchard Therapeutics Announces Strategic Financing Totalling Up To $188 Million

Mar 06, 2023•almost 3 years ago

LondonBiotechnology

Description

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants in a private placement that could bring in up to $188 million at increasing valuations following the achievement of U.S. regulatory milestones for OTL-200 for metachromatic leukodystrophy (MLD).

Company Information

Company

Orchard Therapeutics

Location

245 HAMMERSMITH ROAD

London, England, United Kingdom

About

Orchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment.

Related People

2 contacts

Orchard Therapeutics Announces Strategic Financing Totalling Up To $188 Million

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information